WHO ICTRP trial
Machine learning-based pathomics signature could act as a novel prognostic…
ChiCTR2400083568 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400083568 |
|---|---|
| Public title | Machine learning-based pathomics signature could act as a novel prognostic marker for patients with Esophageal Squamous Cell Carcinoma:A multicenter cohort study |
| Scientific title | Machine learning-based pathomics signature could act as a novel prognostic marker for patients with Esophageal Squamous Cell Carcinoma:A multicenter cohort study |
| Primary sponsor | Fujian Medical University Union Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Prognosis study |
| Phase | Retrospective study |
| Countries | China |
| Conditions | Esophageal Cancer |
| Interventions | Tranning Cohort:None;Internal Validation Cohort:None;External Validation Cohort:None |
| Registration date | Apr 28, 2024 |
| Target size | Tranning Cohort:400;Internal Validation Cohort:87;External Validation Cohort:101 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: